Archives: 2019-08-09

PIER MARIA FORNASARI
2019-08-09

Centers for Medicare & Medicaid Services (CMS) Make CAR T-Cell Cancer Therapy Available to Medicare Beneficiaries Nationwide

Decision ensures consistency in access to the innovative new cancer therapy, and CMS is working closely with sister agencies to monitor outcomes for patients receiving the therapy Today the Centers for Medicare & Medicaid Services (CMS), under the leadership of President Trump and Secretary Azar, finalized the decision to cover FDA-approved Chimeric Antigen Receptor T-cell, or “CAR

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-08-09

Characterizing tau aggregates in neurodegenerative diseases

New research reveals a structural model for amyloid fibrils that could aid in future medicinal interventions for Alzheimer’s, CTE, and more. The microtubule-binding protein tau in neurons of the central nervous system can misfold into filamentous aggregates under certain conditions. These filaments are found in many neurodegenerative diseases such as Alzheimer’s disease, chronic traumatic encephalopathy

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2019-08-09

Apple, Eli Lilly, Evidation Health joint study suggests device sensors can spot cognitive decline

These data provide a proof of concept that Apple products and other consumer devices can play a role in monitoring or identifying disease symptoms. Sensors from consumer-grade devices like iPhones, Apple Watches, iPads and Beddit sleep monitors capture enough data to spot mild cognitive impairment or Alzheimer’s disease dementia, according to a new feasibility study conducted jointly

Read More

No Comments InDIGITAL HEALTH
PIER MARIA FORNASARI
2019-08-09

Remote Patient Monitoring: Medicare Proposes Two Major Expansions

Last week, CMS proposed two significant changes to remote patient monitoring (RPM) services reimbursed under the Medicare program. The changes, part of the proposed 2020 Physician Fee Schedule, have been hotly anticipated by digital health providers hoping to see more clarity and flexibility for RPM services. The creation of new RPM codes at the beginning of 2019 (CPT

Read More

No Comments InDIGITAL HEALTH
PIER MARIA FORNASARI
2019-08-07

Industrial Biotechnology: To What Extent Is Responsible Innovation on the Agenda?

The UK Industrial Biotechnology (IB) Strategy presents a consistent plan to develop the IB sector but fails to endorse an innovation process that allows for input from multiple publics. This could be disadvantageous for the bioeconomy: there are notable cases where negligence to address societal dimensions has caused innovation failure. In 2018, the UK Industrial

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2019-08-07

Muscular contribution to adolescent idiopathic scoliosis from the perspective of stem cell-based regenerative medicine.

Source https://www.liebertpub.com/doi/pdf/10.1089/scd.2019.0073 Adolescent idiopathic scoliosis (AIS) is a relatively frequent disease within a range 0.5-5.0% of population, with higher frequency in females. While a resultant spinal deformity is usually medically benign condition, it produces far going psychosocial consequences, which warrants attention. The etiology of AIS is unknown and current therapeutic approaches are symptomatic only, and

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2019-08-06

MIT researchers automating artificial intelligence for medical decision-making

Model replaces the laborious process of annotating massive patient datasets by hand. MIT computer scientists are hoping to accelerate the use of artificial intelligence to improve medical decision-making, by automating a key step that’s usually done by hand — and that’s becoming more laborious as certain datasets grow ever-larger. The field of predictive analytics holds

Read More

No Comments InDIGITAL HEALTH
PIER MARIA FORNASARI
2019-08-05

Car-T: the first agreement for new therapies, based on actual results, is ready. Martini (Ex Dg Aifa): “A new negotiation model that puts Italy at the forefront”

The first agreement (with Novartis) for therapies that allow to reprogram some cells of the patient (the T lymphocytes), in order to make them able, once reinfused, to recognize and target the tumors, is approved by the CPR and CTS of Aifa. Now the agreement will have to be ratified by the AIFA Board and

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-08-03

University of Minnesota achieves transplant in monkeys without long-term immune-fighting drugs

The technique could greatly increase the number and safety of organ transplants.  University of Minnesota researchers are reporting a breakthrough in what has long been viewed as a holy grail in the field of organ transplantation — success without the permanent need for immunosuppressive drugs. Their technique could greatly increase the number and safety of

Read More

No Comments InCELL THERAPY